Amerge (naratriptan) for migraines
June 1998
Glaxo is now marketing Amerge (naratriptan) for migraines.It's a new oral "triptan"...similar to Imitrex (sumatriptan).
The big difference is that Amerge is longer-acting because ithas a longer half-life.
This means that recurrent headaches are less likely withAmerge than with Imitrex. About 40% of patients using Imitrex haverecurrent headaches because of its short half-life.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote